UPLIZNA (Amgen Australia Pty Ltd)
Product name
UPLIZNA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
166 (175 working days)
Active ingredients
inebilizumab
Registration type
NCE/ NBE
Indication
Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.